These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6465859

  • 21. Enhancing effect of allopurinol on the induction of bladder cancer in rats by n-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
    Wang CY, Hayashida S, Pamukcu AM, Bryan GT.
    Cancer Res; 1976 May; 36(5):1551-5. PubMed ID: 1268818
    [Abstract] [Full Text] [Related]

  • 22. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E.
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [Abstract] [Full Text] [Related]

  • 23. [Epithelial bladder tumor induction in rats with N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide].
    Vlasov NN, Pliss GB, Balin VV.
    Vopr Onkol; 1980 Aug; 26(3):63-7. PubMed ID: 7368659
    [Abstract] [Full Text] [Related]

  • 24. Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide.
    Cohen SM, Wittenberg JF, Bryan GT.
    Cancer Res; 1976 Jul; 36(7 PT 1):2334-9. PubMed ID: 1277139
    [Abstract] [Full Text] [Related]

  • 25. Combined radiotherapy, chemotherapy, and maltose tetrapalmitate immunotherapy in the treatment of 4'dimethylaminoazobenzene-induced liver cancer.
    Nigam VN, Brière N, Bonaventure J, Pageau R, Bissonnette E, Brailovsky C, Madarnas P.
    Anticancer Res; 1986 Jul; 6(2):245-50. PubMed ID: 3085575
    [Abstract] [Full Text] [Related]

  • 26. A long-term study of reversible and progressive urinary bladder cancer lesions in rats fed N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
    Jacobs JB, Arai M, Cohen SM, Friedell GH.
    Cancer Res; 1977 Aug; 37(8 Pt 2):2817-21. PubMed ID: 872108
    [Abstract] [Full Text] [Related]

  • 27. Morphological effects of mitomycin C administered intravesically to normal mice and mice with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induce bladder neoplasms.
    Daskal Y, Soloway MS, DeFuria MD, Crooke ST.
    Cancer Res; 1980 Feb; 40(2):261-7. PubMed ID: 7356509
    [Abstract] [Full Text] [Related]

  • 28. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH.
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [Abstract] [Full Text] [Related]

  • 29. Effect of regenerative hyperplasia on the urinary bladder: carcinogenicity of sodium saccharin and N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
    Cohen SM, Murasaki G, Fukushima S, Greenfield RE.
    Cancer Res; 1982 Jan; 42(1):65-71. PubMed ID: 7053869
    [No Abstract] [Full Text] [Related]

  • 30. Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase.
    Cohen SM, Zenser TV, Murasaki G, Fukushima S, Mattammal MB, Rapp NS, Davis BB.
    Cancer Res; 1981 Sep; 41(9 Pt 1):3355-9. PubMed ID: 6790163
    [Abstract] [Full Text] [Related]

  • 31. Biotransformation of the bladder carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in mice.
    Swaminathan S, Bryan GT.
    Cancer Res; 1984 Jun; 44(6):2331-8. PubMed ID: 6722771
    [Abstract] [Full Text] [Related]

  • 32. The effects of topical instillation of adriamycin in bladder tumors of rats fed with FANFT.
    Pontes JE, Izbicki R, Silberberg B, Baker L, Pierce JM.
    Invest Urol; 1978 Jan; 15(4):278-9. PubMed ID: 627470
    [Abstract] [Full Text] [Related]

  • 33. Effect of peroxidase inhibitors on an in vivo metabolite of the urinary bladder carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats.
    Rice JR, Spry LA, Zenser TV, Davis BB.
    Cancer Res; 1988 Jan 15; 48(2):304-9. PubMed ID: 3121171
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Adjuvant immunotherapy.
    Goodnight JE, Morton DL.
    Int Adv Surg Oncol; 1978 Jan 15; 1():53-83. PubMed ID: 399764
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.